|Videos|March 16, 2023

Analysis of Patients with Transplant-Eligible NDMM with High-Risk Cytogenetic Abnormalities who Received Frontline Daratumumab-Based Quadruplet Therapy

Author(s)Shaji Kumar, MD, Mayo Clinic, Sandy Wong, MD, Alexander Lesokhin, MD

Sandy Wong, MD, presents data from a subgroup analysis of the GRIFFIN and MASTER trials in patients with transplant-eligible NDMM.

Episodes in this series

EP. 1 GRIFFIN Trial in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Final Subgroup Analysis

EP. 1 GRIFFIN Trial in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Final Subgroup Analysis

EP. 2 Treatment Approaches in Transplant-Eligible NDMM

EP. 2 Treatment Approaches in Transplant-Eligible NDMM

EP. 3 Upfront Stem Cell Transplant and Maintenance Therapy in Transplant-Eligible NDMM

EP. 3 Upfront Stem Cell Transplant and Maintenance Therapy in Transplant-Eligible NDMM

EP. 4 Analysis of Patients with Transplant-Eligible NDMM with High-Risk Cytogenetic Abnormalities who Received Frontline Daratumumab-Based Quadruplet Therapy

EP. 4 Analysis of Patients with Transplant-Eligible NDMM with High-Risk Cytogenetic Abnormalities who Received Frontline Daratumumab-Based Quadruplet Therapy

EP. 5 Treatment Approaches in High-Risk Transplant-Eligible NDMM Based on MRD Negativity

EP. 5 Treatment Approaches in High-Risk Transplant-Eligible NDMM Based on MRD Negativity

EP. 6 Planned Interim Analysis of the GMMG-Concept Trial in High-Risk NDMM

EP. 6 Planned Interim Analysis of the GMMG-Concept Trial in High-Risk NDMM

EP. 7 Comparing Quadruplet Combination Treatment Regimens in NDMM

EP. 7 Comparing Quadruplet Combination Treatment Regimens in NDMM

EP. 8 Updated Analysis of the Phase 3 MAIA Study in Transplant-Ineligible Patients with NDMM

EP. 8 Updated Analysis of the Phase 3 MAIA Study in Transplant-Ineligible Patients with NDMM

EP. 9 Clinical Assessment of Key Subgroups of the Phase 3 Maia Study in Transplant-Ineligible Patients with NDMM

EP. 9 Clinical Assessment of Key Subgroups of the Phase 3 Maia Study in Transplant-Ineligible Patients with NDMM

EP. 10 IFM2020-05/Benefit: Isatuximab Plus Lenalidomide, Dexamethasone, and Bortezomib for Elderly Patients with Transplant-Ineligible NDMM

EP. 10 IFM2020-05/Benefit: Isatuximab Plus Lenalidomide, Dexamethasone, and Bortezomib for Elderly Patients with Transplant-Ineligible NDMM

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Related to this article

In a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.

November 4th, 2026

CD38-Targeted Immuno-PET Helps Detect Active Multiple Myeloma

In a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.

“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.

October 29th, 2026

Can a Selinexor Quadruplet Treat Myeloma After T-Cell Redirecting Therapy?

“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.

Trending on CancerNetwork

Building Systems to Catch Liver and Other Cancers in Patients With MASLD

Closing the HCC Surveillance Gap in MASLD Without Cirrhosis

Rethinking Surveillance and Multidisciplinary Care in MASLD-Related HCC

Weighing HCC Surveillance for Patients With MASLD and F3 Fibrosis

Changing Mindsets and Removing Guilt Surrounding Lung Cancer Diagnoses